Digitally engaged physicians about the digital health transition.

BackgroundDigitalisation affects 90% of healthcare. Digital health, however, does not only refer to technological transformation but also has considerable cultural and social consequences. It fundamentally reshapes the roles of physicians and patients, as well as their relationship. Moreover, from the second half of the 20th century, the growing number of chronic patients and the increase in life expectancy have posed new challenges to the medical workforce.ObjectivesTo explore the digitally engaged physician's knowledge and attitudes towards digital health technologies and the transformation of the doctor-patient relationship.MethodsA qualitative interview study analysed with Interpretative Phenomenological Analysis (IPA). The study is based on qualitative, semi-structured interviews with 11 digitally engaged physicians from 9 countries. We identified four main themes emerging from e-physicians' responses and experience: 1) the past: intentions and experiences of change, 2) the present: the role of digital health and technology in the medical practice and their everyday challenges, 3) the present: the practical and ideal physician-patient relationship, and 4) the future: skills and competencies needed for working with e-patients and visions about the future of the medical practice.ResultsThe interviewed physicians state that digital health solutions could create a deeper doctor-patient relationship: knowledgeable patients are a huge help in the joint work effort and technology is the main tool for creating a more involved and responsible patient. Medical professionals in the future might rather get a role as a translator between technical data and the patient; as a guide in the jungle of digital health. However, the interviewed physicians also noted that digital transition today is more beneficial to patients than to their doctors.ConclusionsWe state that digitally engaged physicians are characterized by a kind of dichotomy: they use digital opportunities enthusiastically, but they also feel the difficulties related to digital health

Forecasting Artificial Intelligence Trends in Health Care: Systematic International Patent Analysis

BackgroundArtificial intelligence (AI)– and machine learning (ML)–based medical devices and algorithms are rapidly changing the medical field. To provide an insight into the trends in AI and ML in health care, we conducted an international patent analysis. ObjectiveIt is pivotal to obtain a clear overview on upcoming AI and MLtrends in health care to provide regulators with a better position to foresee what technologies they will have to create regulations for, which are not yet available on the market. Therefore, in this study, we provide insights and forecasts into the trends in AI and ML in health care by conducting an international patent analysis. MethodsA systematic patent analysis, focusing on AI- and ML-based patents in health care, was performed using the Espacenet database (from January 2012 until July 2022). This database includes patents from the China National Intellectual Property Administration, European Patent Office, Japan Patent Office, Korean Intellectual Property Office, and the United States Patent and Trademark Office. ResultsWe identified 10,967 patents: 7332 (66.9%) from the China National Intellectual Property Administration, 191 (1.7%) from the European Patent Office, 163 (1.5%) from the Japan Patent Office, 513 (4.7%) from the Korean Intellectual Property Office, and 2768 (25.2%) from the United States Patent and Trademark Office. The number of published patents showed a yearly doubling from 2015 until 2021. Five international companies that had the greatest impact on this increase were Ping An Medical and Healthcare Management Co Ltd with 568 (5.2%) patents, Siemens Healthineers with 273 (2.5%) patents, IBM Corp with 226 (2.1%) patents, Philips Healthcare with 150 (1.4%) patents, and Shanghai United Imaging Healthcare Co Ltd with 144 (1.3%) patents. ConclusionsThis international patent analysis showed a linear increase in patents published by the 5 largest patent offices. An open access database with interactive search options was launched for AI- and ML-based patents in health care

Pharmacogenetics and pharmacogenomics in rheumatology

Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and Fc gamma R genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology